Ensysce Biosciences, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.6M | $-3.6M | $-2.8M | $-3.7M | $-1.7M | $-1.9M | $-3.6M | $661.8K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $6.5K | $6.5K | $6.5K | $0 | $0 | $0 | $0 | $0 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.9K | $8.7K | $24.3K | $-50.3K | $186.8K | $16.3K | $30.1K | $20.8K |
| Net Cash from Operating Activities | $-2.0M | $-3.5M | $-1.5M | $-1.9M | $-2.7M | $-1.7M | $-764.1K | $-1.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.9M | $-63.9K | $4.2M | $1.5M | $1.9M | $1.3M | $112.6K | $4.1M |
| Net Change in Cash | $-68.8K | $-3.6M | $2.6M | $-538.4K | $-840.9K | $-449.6K | $-651.5K | $3.1M |
| Free Cash Flow | — | — | — | — | — | — | — | — |